PRAVIGARD PAC (COPACKAGED)
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PRAVIGARD PAC (COPACKAGED) (PRAVIGARD PAC (COPACKAGED)).
Pravigard PAC (copackaged) contains pravastatin, an HMG-CoA reductase inhibitor that competitively inhibits the conversion of HMG-CoA to mevalonate, reducing cholesterol synthesis, and buffered aspirin, which irreversibly acetylates cyclooxygenase (COX-1 and COX-2), inhibiting thromboxane A2 synthesis and platelet aggregation.
| Metabolism | Pravastatin undergoes minimal hepatic metabolism via CYP3A4 (minor pathway) and is primarily excreted unchanged in urine and feces. Aspirin is rapidly hydrolyzed to salicylic acid, which is conjugated with glycine (salicyluric acid) and glucuronic acid in the liver. |
| Excretion | Pravastatin: ~20% renal, ~70% fecal (biliary); Aspirin: renal (dose-dependent, ~50-80% as salicylates, ~10-20% as salicyluric acid) |
| Half-life | Pravastatin: 1.5-2 hours (terminal, clinical significance minimal due to prolonged HMG-CoA reductase inhibition); Aspirin: 15-20 minutes (acetylated form), salicylate: 2-3 hours (low dose) to 15-30 hours (high dose, due to saturable metabolism) |
| Protein binding | Pravastatin: ~50% bound (albumin); Aspirin: dose-dependent, 50-90% bound (albumin) for salicylate |
| Volume of Distribution | Pravastatin: 0.46 L/kg; Aspirin: 0.15-0.2 L/kg (salicylate: 0.1-0.35 L/kg, increased in acidosis) |
| Bioavailability | Pravastatin: oral, 34% (tablet); Aspirin: oral, 100% (immediate-release), but systemic bioavailability of active aspirin is limited due to presystemic hydrolysis (40-50% for enteric-coated) |
| Onset of Action | Pravastatin: oral, 1-2 weeks for lipid-lowering effect; Aspirin: oral immediate-release, 30-60 minutes for antiplatelet effect; enteric-coated, 3-4 hours |
| Duration of Action | Pravastatin: 24 hours (clinical lipid-lowering, taken once daily); Aspirin: platelet inhibition for lifespan of platelet (7-10 days), analgesic/antipyretic 4-6 hours |
PRAVIGARD PAC (copackaged) is not a single drug but a copackaged product containing pravastatin and aspirin. The typical adult dose of pravastatin is 40 mg orally once daily; aspirin is 81 mg orally once daily. Both are taken together as a single daily dose.
| Dosage form | TABLET |
| Renal impairment | For pravastatin: No dose adjustment is recommended for mild to moderate renal impairment. In severe renal impairment (CrCl <30 mL/min), start with 10 mg orally once daily and titrate cautiously. Aspirin: Avoid in severe renal impairment (GFR <30 mL/min/1.73m²) due to increased risk of bleeding and renal toxicity. For CrCl 30-60 mL/min, no adjustment specified. |
| Liver impairment | Pravastatin is contraindicated in active liver disease or unexplained persistent transaminase elevations. For Child-Pugh Class A or B: No specific dose adjustment provided; use with caution. For Child-Pugh Class C: Not studied; avoid. Aspirin: Use with caution in hepatic impairment; avoid in severe hepatic insufficiency due to risk of bleeding and fluid retention. |
| Pediatric use | Pravastatin: Not recommended for pediatric patients <8 years. For ages 8-18 with heterozygous familial hypercholesterolemia: 20 mg orally once daily for ages 8-13; 40 mg orally once daily for ages 14-18. Aspirin: Use not advisable in children due to risk of Reye's syndrome; avoid use except in specific pediatric conditions (e.g., Kawasaki disease) under specialist guidance. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PRAVIGARD PAC (COPACKAGED) (PRAVIGARD PAC (COPACKAGED)).
| Breastfeeding | Pravastatin is excreted in human breast milk in low levels (M/P ratio unknown for combination). Aspirin is excreted in breast milk with M/P ratio approximately 0.03-0.4. Due to potential for adverse effects in nursing infant (e.g., Reye's syndrome with aspirin), breastfeeding is not recommended during Pravigard PAC therapy. |
| Teratogenic Risk | Pravigard PAC contains pravastatin (Pregnancy Category X) and aspirin. First trimester: aspirin use associated with increased risk of gastroschisis; statins contraindicated due to risk of fetal malformations. Second trimester: aspirin may increase risk of intracranial hemorrhage in fetus. Third trimester: aspirin increases risk of premature closure of ductus arteriosus and oligohydramnios; statins may impair fetal development. |
■ FDA Black Box Warning
Reye's syndrome: Aspirin should not be used in children and teenagers with viral infections due to risk of Reye's syndrome.
| Serious Effects |
["Hypersensitivity to pravastatin, aspirin, or any component","Active hepatic disease or unexplained persistent elevations of serum transaminases with pravastatin","Pregnancy and lactation (aspirin and pravastatin)","Children and teenagers with viral infections (aspirin, Reye's syndrome risk)","Bleeding disorders (e.g., hemophilia, von Willebrand disease) with aspirin"]
| Precautions | ["Risk of bleeding (e.g., gastrointestinal, intracranial) due to aspirin","Hepatic impairment: monitor liver function tests with pravastatin","Renal impairment: pravastatin dose adjustment may be required","Hypersensitivity reactions to aspirin or pravastatin","Peptic ulcer disease or gastrointestinal bleeding history with aspirin"] |
Loading safety data…
| Geriatric use | Pravastatin: No specific dose adjustment required for elderly; consider lower starting doses (e.g., 10 mg) due to increased risk of myopathy and age-related renal decline. Aspirin: Use lowest effective dose (e.g., 81 mg daily) due to increased risk of gastrointestinal bleeding. Monitor renal function and bleeding risk. |
| Fetal Monitoring | Monitor liver function tests at baseline and periodically; monitor creatine kinase if symptoms of myopathy; monitor coagulation parameters if high-dose aspirin; fetal ultrasound for ductus arteriosus and amniotic fluid index in third trimester if aspirin continued. |
| Fertility Effects | Pravastatin may reduce cholesterol, a precursor for steroid hormone synthesis, potentially impairing fertility. Aspirin at high doses may inhibit prostaglandin synthesis, affecting ovulation and implantation. Reversible upon discontinuation. |